glofitamab sold brand name columvi bispecific monoclonal antibody used treatment diffuse large bcell bispecific tcell approved medical use canada march united states june european union july glofitamab indicated treatment adults relapsed refractory diffuse large bcell us food drug administration fda label includes boxed warning serious fatal cytokine release april committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product columvi intended treatment diffuse large lymphoma applicant medicinal product roche registration glofitamab approved medical use european union july glofitamab international nonproprietary httpsenwikipediaorgwikiglofitamab